Webb21 dec. 2024 · Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in … WebbPhio Pharmaceuticals Publications Our Science Immuno-Oncology Intasyl™ TECHNOLOGY Publications Publications 2024 Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors. Annals of Oncology, 2024, Volume 32, Supplement 5. …
Phio Pharmaceuticals Announces New Clinical Program to Study …
Phio's technology platform (INTASYL) allows the development of 'self-delivering’ RNAi compounds, or 'sd-rxRNA' for short, in which drug-like properties were built into the RNAi compound itself, rather than relying on liposomal delivery to improve circulation time and cellular uptake. This platform was developed through systematic medicinal chemistry screening and they have shown the utility of their platform in three papers. WebbPhio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing ... cst school meaning
Phio Pharmaceuticals About Us
WebbINTASYL™ is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL™ drugs precisely target specific proteins that reduce the body’s … Webb11 mars 2024 · MARLBOROUGH, Mass., March 11, 2024 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next … Webb4 apr. 2024 · MARLBOROUGH, Mass., Nov. 10, 2024 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended September … cst scholarship login